ETOILE: Real-World Evidence of 24 Months of Ranibizumab 0.5 mg in Patients with Visual Impairment Due to Diabetic Macular Edema

Figures & data

Figure 1 Flow chart of patients in study.

Table 1 Patient and Studied Eye Baseline Characteristics

	Total (N=105)
Mean age (SD) (years)	65.5 (11.4)
Male gender, n (%)	62 (59.0)
Diabetes type, n (%)
Type I	15 (14.3)
Type II	90 (85.7)
Years since diagnosis of diabetes, mean (SD)	17.9 (10.2)
Mean HbA1c % (SD)	7.7 (1.2)
HbA1c ≥ 8%, n (%)	24 (31.6)
Months since DME diagnosis, mean (SD)	12.4 (25.6)
≤3 months since DME diagnosis, n (%)	52 (50.0)
DME type, n (%)
Diffuse	52 (66.7)
Focal	20 (25.6)
Mixed	6 (7.7)
Bilateral DME, n (%)	80 (76.2)
Months to bilateral DME, mean (SD)	3.12 (16.7)
Diabetic retinopathy, n (%)	78 (74.3)
Non-proliferative, n (%)	60 (75.0)
Proliferative, n (%)	18 (22.5)
Visual acuity in ETDRS letters, mean [95% CI]	58.4 [55.7, 61.0]
Patients with BCVA ≤69, n (%)	75 (71.4)
Patients with VA letter score ≥69, n (%)	30 (28.6)
CRT (μm), mean [95% CI]	480.7 [455.7, 505.7]
CRT < 350, n (%)	16 (15.5)
CRT ≥ 350, n (%)	87 (84.5)
Intraocular pressure (mmHg), mean (SD)	15.4 (3.0)
Macular volume (mm^3), mean (SD)	10.7 (2.2)
Other anatomical features
Serous retinal detachment, n (%)	27 (26.0)
Loss of integrity of external limiting membrane, n (%)	43 (41.7)
Loss of integrity of the internal/external segment, n (%)	50 (48.5)
Retrofoveolar exudates, n (%)	28 (27.2)
Foveolar atrophy, n (%)	4 (3.9)
Epiretinal membrane, n (%)	20 (19.2)

Note: Percentages were calculated for the number of patients with available data for each variable.

Abbreviations: CRT, central retinal thickness; DME, diabetic macular edema; SD, standard deviation; VA, visual acuity; HbA1c, glycosylated hemoglobin.

Figure 2 Change from baseline in (A) visual acuity and, (B) central retinal thickness.

Figure 3 Change from baseline in (A) visual acuity and (B) central retinal thickness, according to completion of induction phase.

Figure 4 Change from baseline in visual acuity in patients (A) without and (B) with treatment switch, and change from baseline in central retinal thickness in patients (C) without and (D) with treatment switch.